US FDA and European Medicines Agency accept applications for high-strength adalimumab biosimilar (AVT02)

AVT02 is a proposed adalimumab biosimilar with high concentration (100mg/mL) dosage forms, matching the newest dosage forms of the reference product Humira®. The application includes data from comparative pharmacokinetic and clinical efficacy and safety studies.

Source:

Biospace Inc.